 | | Vol. 13.10 – 19 March, 2021 |
| |
|
|
| Researchers examined how immunity was integrated within adult mouse tissues, and addressed issues of durability, expansibility and contributions to organ cellularity.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To investigate how nutrient uptake is regulated in the small intestine, scientists tested the effect of diets with different macronutrient compositions on epithelial gene expression.
[Science] |
|
|
|
| Interleukin-10 (IL-10) variants with a range of IL-10 receptor β binding strengths uncovered substantial differences in response thresholds across immune cell populations, providing a means of manipulating IL-10 cell type selectivity.
[Science] |
|
|
|
| Researchers demonstrated that migration of donor leukocytes out of skin or heart allografts is not necessary for B or T cell allosensitization in mice.
[Science Translational Medicine] |
|
|
|
| Linc00402 was increased in donor T cells from patients who underwent allogeneic cardiac transplantation and in murine T cells.
[Science Translational Medicine] |
|
|
|
| Investigators showed that macrophages elicited into the peritoneal cavity during mild inflammation persist long-term but were retained in an immature transitory state of differentiation due to the presence of enduring resident macrophages.
[Nature Communications] |
|
|
|
| The natural mechanisms limiting myeloid-derived suppressor cells activity are not well understood. Scientists present evidence that type I interferons receptor signaling serves as a universal mechanism that restricts acquisition of suppressive activity by these cells.
[Nature Communications] |
|
|
|
| Researchers constructed a single-cell atlas of mouse mandibular alveolar bone through single-cell RNA sequencing. A more active immune microenvironment was identified in alveolar bone, with a higher proportion of mature immune cells than in long bone.
[Bone Research] |
|
|
|
| Scientists demonstrated that although inhibition of xCT either by pharmacological inhibitor or genetic knockdown induced ROS-related death in melanoma cells, inhibition of xCT significantly reduced the efficacy of anti-PD-1/PD-L1 immune checkpoint blockade through upregulating PD-L1 expression via the transcription factors IRF4/EGR1.
[Molecular Therapy] |
|
|
|
| The authors profiled genome-wide changes in chromatin accessibility, gene transcription, and the deposition of a key chromatin modification early after naive CD8+ T cell activation.
[Cell Reports] |
|
|
|
| Researchers investigated the functional outcome of T-T cell antigen presentation by CD4 T cells and found that the antigen-presenting T cells (Tpres) predominantly differentiated into Treg cells, whereas T cells that were stimulated by Tpres cells predominantly differentiated into Th17 pro-inflammatory cells.
[Cell Reports] |
|
|
|
| Scientists found that interleukin-7 signaling promoted the accumulation of tumor-associated CD8+ T cells, in part, by preventing adenosine-mediated immunosuppression.
[Science Signaling] |
|
|
|
|
| Researchers describe the current understanding of protein N-myristoylation and summarize its crucial roles in regulating innate immune responses, including TLR4-dependent inflammatory responses and demyristoylation-induced innate immunosuppression during Shigella flexneri infection.
[Cellular & Molecular Immunology] |
|
|
|
| The authors discuss studies revealing the immune evasion mechanism by N6-methyladenosine modification, which underlies the retouching of these signaling networks and the rapid tolerance of innate and adaptive immune molecules during disease.
[Cell Death & Disease] |
|
|
|
|
| T-Cure Bioscience, Inc. announced that the company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, such as gastric, cervical, lung, and triple negative breast cancers.
[T-Cure Bioscience, Inc. (Business Wire, Inc.)] |
|
|
|
| Anokion SA announced that the company has initiated patient dosing in the multiple ascending dose portion of its Assessment of KAN-101 in Celiac Disease disease, a Phase I clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease.
[Anokion SA] |
|
|
|
| AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application for upadacitinib in the treatment of adult patients with active psoriatic arthritis.
[AbbVie] |
|
|
|
| CARISMA Therapeutics Inc. announced that the first patient has been dosed in the Phase I multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 targeted chimeric antigen receptor macrophage.
[CARISMA Therapeutics Inc.] |
|
|
|
|
| April 11 – 13, 2021
San Diego, California, United States |
|
|
|
|
|
| | NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| | University of Toronto – Toronto, Ontario, Canada |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
